OncoMatch/Clinical Trials/NCT05926765
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
Is NCT05926765 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for grade 2 and 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tract, excluding the parotid glands.
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Must have received: beam radiation therapy — head and neck cancer
Completed beam radiation therapy for head and neck cancer at least 3 years prior to the first screening visit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Banner MD Anderson Cancer Center · Gilbert, Arizona
- City of Hope · Duarte, California
- Miami Cancer Institute at Baptist Health South Florida · Miami, Florida
- University of Iowa · Iowa City, Iowa
- Johns Hopkins Hospital · Baltimore, Maryland
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify